Drug intelligence / Profile preview

S1B-509

Development stage: Phase 2
Lead developer: S1 Biopharma, Inc.
Modality: Small Molecules
Administration: Oral

Overview

S1B-509 is an investigational small molecule drug developed by S1 Biopharma for the treatment of obesity and weight loss. It is currently in Phase 2 clinical trials, where it is being evaluated for its efficacy and safety in helping individuals with overweight or obesity lose weight compared to placebo. The drug is administered orally on a daily basis, with ongoing studies assessing changes in body weight and related metabolic parameters over a one-year period. The precise mechanism of action of S1B-509 has not been disclosed publicly.

Beyond the preview

Go deeper on S1B-509.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S1B-509.

Explore the full profile